QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that its board of directors has authorized the repurchase of up to $300 million of shares of QuidelOrtho’s common stock over the next two years.
Maxim Group Maintains Buy on Usio, Lowers Price Target to $5
Maxim Group analyst Michael Diana maintains Usio (NASDAQ:USIO) with a Buy and lowers the price target from $8 to $5.
